P
Philippe Lorimier
Researcher at University of Grenoble
Publications - 20
Citations - 4298
Philippe Lorimier is an academic researcher from University of Grenoble. The author has contributed to research in topics: Cancer & TUNEL assay. The author has an hindex of 13, co-authored 20 publications receiving 3913 citations. Previous affiliations of Philippe Lorimier include Joseph Fourier University.
Papers
More filters
Journal ArticleDOI
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer,Lynnette Fernandez-Cuesta,Martin L. Sos,Julie George,Danila Seidel,Lawryn H. Kasper,Dennis Plenker,Frauke Leenders,Ruping Sun,Thomas Zander,Roopika Menon,Mirjam Koker,Ilona Dahmen,Christian Müller,Vincenzo Di Cerbo,Hans Ulrich Schildhaus,Janine Altmüller,Ingelore Baessmann,Christian Becker,Bram De Wilde,Jo Vandesompele,Diana Böhm,Sascha Ansén,Franziska Gabler,Ines Wilkening,Stefanie Heynck,Johannes M. Heuckmann,Xin Lu,Scott L. Carter,Kristian Cibulskis,Shantanu Banerji,Gad Getz,Kwon-Sik Park,Daniel Rauh,Christian Grütter,Matthias Fischer,Laura Pasqualucci,Gavin M. Wright,Zoe Wainer,Prudence A. Russell,Iver Petersen,Yuan Chen,Erich Stoelben,Corinna Ludwig,Philipp A. Schnabel,Hans Hoffmann,Thomas Muley,Michael Brockmann,Walburga Engel-Riedel,Lucia Anna Muscarella,Vito Michele Fazio,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egber Smit,Daniëlle A M Heideman,Peter J.F. Snijders,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Steinar Solberg,Odd Terje Brustugun,Marius Lund-Iversen,Jörg Sänger,Joachim H. Clement,Alex Soltermann,Holger Moch,Walter Weder,Benjamin Solomon,Jean-Charles Soria,Pierre Validire,Benjamin Besse,Elisabeth Brambilla,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Peter M. Schneider,Michael Hallek,William Pao,Matthew Meyerson,Matthew Meyerson,Julien Sage,Jay Shendure,Robert Schneider,Robert Schneider,Reinhard Büttner,Jürgen Wolf,Peter Nürnberg,Sven Perner,Lukas C. Heukamp,Paul K. Brindle,Stefan A. Haas,Roman K. Thomas +94 more
TL;DR: This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Journal ArticleDOI
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss,Martin L. Sos,Danila Seidel,Martin Peifer,Thomas Zander,Johannes M. Heuckmann,Roland T. Ullrich,Roopika Menon,Sebastian Maier,Alex Soltermann,Holger Moch,Patrick Wagener,Florian Fischer,Stefanie Heynck,Mirjam Koker,Jakob Schöttle,Frauke Leenders,Franziska Gabler,Ines Dabow,Silvia Querings,Lukas C. Heukamp,Hyatt Balke-Want,Sascha Ansén,Daniel Rauh,Ingelore Baessmann,Janine Altmüller,Zoe Wainer,Matthew Conron,Gavin M. Wright,Prudence A. Russell,Ben Solomon,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Steinar Sollberg,Odd Terje Brustugun,Walburga Engel-Riedel,Corinna Ludwig,Iver Petersen,Jörg Sänger,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egbert F. Smit,Daniëlle A.M. Heideman,Federico Cappuzzo,C. Ligorio,Stefania Damiani,Michael Hallek,Rameen Beroukhim,William Pao,Bert Klebl,Matthias Baumann,Reinhard Buettner,Karen Ernestus,Erich Stoelben,Jürgen Wolf,Peter Nürnberg,Peter Nürnberg,Sven Perner,Roman K. Thomas +62 more
TL;DR: F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
Journal ArticleDOI
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Peter S. Hammerman,Martin L. Sos,Alex H. Ramos,Chunxiao Xu,Amit Dutt,Wenjun Zhou,Lear E. Brace,Brittany Woods,Wenchu Lin,Jianming Zhang,Xianming Deng,Sang Min Lim,Stefanie Heynck,Martin Peifer,Jeffrey R. Simard,Michael S. Lawrence,Robert C. Onofrio,Helga B. Salvesen,Danila Seidel,Thomas Zander,Johannes M. Heuckmann,Alex Soltermann,Holger Moch,Mirjam Koker,Frauke Leenders,Frauke Leenders,Franziska Gabler,Silvia Querings,Sascha Ansén,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Odd Terje Brustugun,Åslaug Helland,Iver Petersen,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erich Stoelben,Juergen Wolf,David G. Beer,Ming-Sound Tsao,Megan Hanna,Megan Hanna,Charlie Hatton,Charlie Hatton,Michael J. Eck,Pasi A. Jänne,Bruce E. Johnson,Wendy Winckler,Heidi Greulich,Heidi Greulich,Adam J. Bass,Jeonghee Cho,Daniel Rauh,Nathanael S. Gray,Kwok-Kin Wong,Eric B. Haura,Roman K. Thomas,Matthew Meyerson,Matthew Meyerson +61 more
TL;DR: Findings suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib, and provide a rationale for designing clinical trials with the FDA-approved drug d asatinib in patients with lung SCCs.
Journal ArticleDOI
A genomics-based classification of human lung tumors
Danila Seidel,Thomas Zander,Lukas C. Heukamp,Martin Peifer,Marc Bos,Lynnette Fernandez-Cuesta,Frauke Leenders,Xin Lu,Sascha Ansén,Masyar Gardizi,Chau Nguyen,Chau Nguyen,Johannes Berg,Prudence A. Russell,Zoe Wainer,Hans-Ulrich Schildhaus,Hans-Ulrich Schildhaus,Toni-Maree Rogers,Benjamin Solomon,William Pao,Scott L. Carter,Gad Getz,D. Neil Hayes,Matthew D. Wilkerson,Erik Thunnissen,William D. Travis,Sven Perner,Gavin M. Wright,Elisabeth Brambilla,Reinhard Buettner,Juergen Wolf,Roman K. Thomas,Franziska Gabler,Ines Wilkening,Christian Mueller,Ilona Dahmen,Roopika Menon,Katharina Koenig,Kerstin Albus,Sabine Merkelbach-Bruse,Jana Fassunke,Katja Schmitz,Helen Kuenstlinger,Michaela Angelika Kleine,Elke Binot,Silvia Querings,Janine Altmueller,Ingelore Boessmann,Peter Nuemberg,Peter M. Schneider,Magdalena Bogus,Alex Soltermann,Holger Moch,Odd Terje Brustugun,Steinar Solberg,Marius Lund-Iversen,Åslaug Helland,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Yuan Chen,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Joachim H. Clement,Walter Weder,Joerg Saenger,Erich Stoelben,Corinna Ludwig,Walburga Engel-Riedel,Egbert F. Smit,Danille A. M. Heideman,Peter J.F. Snijders,Lucia Nogova,Martin L. Sos,Christian Mattonet,Karin Toepelt,Matthias Scheffler,Eray Goekkurt,Eray Goekkurt,Rainer Kappes,Stefan Krueger,Kato Kambartel,Dirk Behringer,Wolfgang Schulte,Wolfgang Galetke,Winfried Randerath,Matthias Heldwein,Andreas Schlesinger,Monika Serke,Khosro Hekmat,Konrad Frank,Roland Schnell,Marcel Reiser,Ali-Nuri Huenerlituerkoglu,Stephan Schmitz,Lisa Meffert,Yon-Dschun Ko,Markus Litt-Lampe,Ulrich Gerigk,Rainer Fricke,Benjamin Besse,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Denis Moro-Sibilot,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Russell Hyde,Pierre Validire,Philippe Girard,Lucia Anna Muscarella,Vito Michele Fazio,Michael Hallek,Jean-Charles Soria,Viktor Achter,Ulrich Lang +118 more
TL;DR: Support is provided for broad implementation of genome-based diagnosis of lung cancer by demonstrating the correlation between lung tumor subtype and its predominant mutations, and the benefit of genetic testing and targeted therapy in these patients.
Journal ArticleDOI
In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations.
A. Negoescu,Philippe Lorimier,Françoise Labat-Moleur,Christian Drouet,Catherine Robert,Christiane Guillermet,Christian Brambilla,Elisabeth Brambilla +7 more
TL;DR: The results showed that with an adequate pretreatment, reliable TUNEL can be obtained after each fixative tested, and the existence of a limited population of intensely TUNel-positive cells that lacked apoptotic morphology contributes to the current debate about a preapoptotic state.